Abstract
Prostate cancer (PC) is the most common malignancy in males. Despite high response rates and clinical benefits, androgen-ablation therapy is ineffective for advanced or relapsed PC because of the emergence of aggressive castration-resistant prostate cancer (CRPC). Through our genome-wide gene expression analysis of PC cells purified from clinical CRPC tissues, we here identified a novel molecular target, PKIB (cAMP-dependent protein kinase inhibitor-β), which was overexpressed specifically in CRPCs and aggressive PCs. Immunohistochemical analysis confirmed its overexpression in CRPCs and its strong correlation with high Gleason scores of PCs. Knockdown of PKIB by siRNA resulted in drastic growth suppression of PC cells, and, concordantly, exogenous introduction of PKIB into PC cells enhanced their growth and mobility. We found the direct interaction between PKIB and cAMP-dependent protein kinase A catalytic subunit (PKA-C), and showed that knockdown of PKIB in PC cells diminished the nuclear translocation of PKA-C. Knockdown of PKIB also decreased the phosphorylation level of Akt at Ser473 in PC cells, and exogenous PKIB introduction enhanced Akt phosphorylation in PC cells by incorporating with endogenous PKA-C kinase. In vitro kinase assay validated the recombinant PKIB enhanced phosphorylation of Akt at Ser473 by PKA-C kinase. These findings show that PKIB and PKA-C kinase can have critical functions of aggressive phenotype of PCs through Akt phosphorylation and that they should be a promising molecular target for PC treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Burgering BM, Kops GJ . (2002). Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27: 352–360.
Chio CC, Chang YH, Hsu YW, Chi KH, Lin WW . (2004). PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. Cell Signal 16: 565–575.
Cox ME, Deeble PD, Bissonette EA, Parsons SJ . (2000). Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendcrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 275: 13812–13818.
Dalton GD, Dewey WL . (2006). Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides 40: 23–34.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241.
Deeble PD, Cox ME, Frieson Jr HF, Sikes RA, Palmer JB, Davidson RJ et al. (2007). Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67: 3663–3672.
Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM . (1998). Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743–1748.
Feldman BJ, Feldman D . (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.
Filippa N, Sable C, Filloux C, Hemmings B, Van Obberghen E . (1999). Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 19: 4989–5000.
Gamm DM, Uhler MD . (1995). Isoform–specific differences in the potencies of murine protein kinase inhibitors are due to unconserved amino-terminal residues. J Biol Chem 270: 7227–7232.
Gronberg H . (2003). Prostate cancer epidemiology. Lancet 361: 859–864.
Grossmann ME, Huang H, Tindall DJ . (2001). Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 93: 1687–1697.
Hay N . (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179–183.
Hsing AW, Devesa SS . (2001). Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3–13.
Knighton DR, Zheng JH, Teneyck LF, Xuong NH, Taylor SS, Sowadski JM . (1991). Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253: 414–420.
Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. (2004). Phosphorylation of Akt(Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232–5236.
Lalli E, Sassone-Corsi P . (1994). Signal transduction and gene regulation: the nuclear response to cAMP. J Biol Chem 269: 17359–17362.
Majumder PK, Sellers WR . (2005). Akt-regulated pathways in prostate cancer. Oncogene 24: 7465–7474.
Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al. (2002). Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168–1171.
McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V et al. (2008). Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68: 1618–1624.
Miller WR . (2002). Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci 968: 37–48.
Mitsiades CS, Mitsiades N, Koutsilieris M . (2004). The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4: 235–256.
Orloff MS, Eng C . (2008). Genetic and phenotypic heterogeneity in the PTEN hamartoma tumor syndrome. Oncogene 27: 5387–5397.
Pap M, Cooper GM . (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273: 19929–19932.
Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. (2004). Docetaxel and estramustine compared with mitoxantrone and predonisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520.
Sadar MD . (1999). Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274: 7777–7783.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . (2005). Phosphorylation and regulation of Akt/PKB by Rictor-mTOR complex. Science 307: 1098–1101.
Scheid MP, Woodgett JR . (2001). PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2: 760–768.
Scher HI, Sawyers CL . (2006). Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253–8261.
Shaywitz AJ, Greenberg ME . (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821–861.
Stork PJ, Schmitt JM . (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258–266.
Tamura K, Furihata M, Tsunoda T, Ashida A, Takata R, Obara W et al. (2007). Molecular features of hormone-refractory prostate cancer cells by genome-wide gene-expression profiles. Cancer Res 67: 5117–5125.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. (2004). Docetaxel plus predonisone or mitoxantrone plus predonisone for advanced prostate cancer. N Engl J Med 351: 1502–1512.
Tasken K, Aandahl EM . (2004). Localized effects of cAMP mediated by distinct routes of protein kinase A. Physol Rev 84: 137–167.
Taylor SS, Kim C, Vigil D, Haste NM, Yang J, Wu J et al. (2005). Dynamics of signaling by PKA. Biochim Biophys Acta 1754: 25–37.
Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2: 289–301.
Wen W, Harootunian AT, Admas SR, Feramisco J, Tsien RY, Meinkoth JL et al. (1994). Heat-stable inhibitors of cAMP-dependent protein kinase carry a nuclear export signal. J Biol Chem 269: 32214–32220.
Wiley JC, Wailes LA, Idzerda RL, McKnight GS . (1999). Role of regulatory subunits and protein kinase inhibitor (PKI) in determining nuclear localization and activity of the catalytic subunit of protein kinase A. J Biol Chem 274: 6381–6387.
Acknowledgements
We would like to thank Ms Mami U and Ms Hitomi Uchida for their technical assistance, and Dr Ryo Takada at Iwate Medical University for his preparation of prostate cancer tissues. This work was supported by Grant-in-Aid for Scientific Research #18590323 (H Nakagawa) and Research for the Future Program Grants #00L01402 (Y Nakamura) from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Chung, S., Furihata, M., Tamura, K. et al. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene 28, 2849–2859 (2009). https://doi.org/10.1038/onc.2009.144
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.144
Keywords
This article is cited by
-
Downregulation of cAMP-Dependent Protein Kinase Inhibitor-b Promotes Preeclampsia by Decreasing Phosphorylated Akt
Reproductive Sciences (2021)
-
OMICfpp: a fuzzy approach for paired RNA-Seq counts
BMC Genomics (2019)
-
Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population
Medical Oncology (2012)
-
PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype
Medical Molecular Morphology (2012)
-
k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction
The Pharmacogenomics Journal (2010)